Fudan University Cancer Center Trials

Fudan University Cancer Center	Welcome, Profile Billing Logout

72 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Wang, Zhonghua

Renaissance, NCT05076682: Reverse Triple Negative Immune Resistant Breast Cancer

Recruiting

RoW

Choline, anti-PD-1 antibody and chemotherapy, Sodium Cromoglicate, Efavirenz

Fudan University

Triple-negative Breast Cancer

12/22

03/23

Resilire, NCT06731140: Reverse Luminal Immune Resistant Breast Cancer

Recruiting

RoW

Retinoic Acid, anti-PD-1 antibody and chemotherapy

Fudan University

Luminal Breast Cancer

07/26

10/26

Chen, Haiquan

NCT06634966: Segmentectomy for Solid-dominant Lung Cancer

Recruiting

277

RoW

Segmentectomy, Segment resection

Fudan University

Segmentectomy, Lung Adenocarcinoma

12/26

06/27

NCT06031246: Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018)

Recruiting

634

RoW

Selective Lymph Node Dissection

Fudan University

Lung Adenocarcinoma, Lymph Node Metastasis

01/26

12/30

SEFOGI, NCT05717803: Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012)

Recruiting

307

RoW

Segmentectomy, Segment resection, Segment removal

Fudan University

Segmentectomy, Lung Adenocarcinoma

12/28

12/29

ACTPI, NCT03380468: Adjuvant Chemotherapy for High Risk Stage I Lung Adenocarcinoma

Recruiting

2/3

300

RoW

cisplatin plus pemetrexed

Fudan University

Lung Neoplasms

01/24

12/25

HYPERION, NCT05281003: Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)

Recruiting

128

RoW

Pembrolizumab, Keytruda, MK-3475, Paclitaxel, Cisplatin

Fudan University, Merck Sharp & Dohme LLC

Esophageal Squamous Cell Carcinoma

09/23

09/26

NCT06152978: A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma

Not yet recruiting

182

RoW

Sintilimab, Chemotherapy

Fudan University, Innovent Biologics (Suzhou) Co. Ltd.

Esophageal Squamous Cell Carcinoma

12/25

12/27

NCT06572722: Perioperative Immunotherapy for NSCLC (ECTOP-1030)

Not yet recruiting

200

Atezolizumab, Nivolumab, Pembrolizumab

Fudan University

Lung Cancer

09/26

09/29

NCT03591445: Is Bronchoscopy Necessary in the Preoperative Workup of GGO Lung Cancer?(ECTOP-1005)

Completed

N/A

615

RoW

Flexible Bronchoscopy

Fudan University, Henan Cancer Hospital, Anhui Chest Hospital, Shanghai Zhongshan Hospital, Affiliated Hospital of Jiangnan University, Jilin Provincial Tumor Hospital, Guanxian Central Hospital of Shandong Province, The Third people's Hospital of Jieyang, Queen Mary Hospital, Hong Kong, Jiangdu people's hospital of Yangzhou Jiangsu Province

Pulmonary Nodule, Solitary

11/19

06/20

NCT03689439: Is Bone Scintigraphy Necessary in cT1N0M0 GGO Non-Small Cell Lung Cancer? (ECTOP-1006)

Completed

N/A

1000

RoW

bone scintigraphy

Fudan University

Bone Metastases

11/21

11/22

NCT05252676: Evaluation of Correlations Between Radiologic Features and Pathologic Subtypes of GGO LUAD Via WMS (ECTOP-1011)

Completed

N/A

103

RoW

Fudan University

Adenocarcinoma of Lung

08/22

12/22

NCT04527419: SLND or Not in cT1 GGO Invasive Lung Adenocarcinoma (ECTOP-1009)

Recruiting

N/A

638

RoW

Systematically mediastinal lymph node dissection, No mediastinal lymph node dissection

Fudan University

Carcinoma, Non-Small-Cell Lung

02/24

02/27

NCT06634979: Selective Lymph Node Resection for Invasive Non-small Cell Lung Cancer with the CTR of 0.5-1 and the Diameter of ≤ 2 Cm

Recruiting

N/A

684

RoW

Selective lymph node dissection

Fudan University

Lung Cancer (NSCLC), Lymph Node Dissection

05/26

05/29

NCT05443841: Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)

Recruiting

N/A

385

RoW

pleural lavage

Fudan University

Esophageal Cancer

07/24

07/27

Fu, Xiao-Long

NCT05177497: SHR-1701 for Consolidation Therapy After Concurrent Chemoradiotherapy in Inoperable Stage III NSCLC

Not yet recruiting

SHR-1701

Shanghai Chest Hospital

NSCLC, Stage III

07/24

10/24

Xiang, Jiaqing

NCT03273647: Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma With Positive Circumstantial Resection Margin

Not yet recruiting

radiation

Fudan University

Esophageal Squamous Cell Carcinoma, Positive Circumferential Resection Margin

12/19

12/24

Zhao, Kuaile

NCT06190782: Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor

Recruiting

354

RoW

PD-1 inhibitor+/- chemotherapy combined with local therapy, systemic therapy alone, the systemic therapy only

Fudan University

Esophageal Squamous Cell Carcinoma, Oligometastatic Disease, Radiotherapy

09/25

09/27

NCT03790553: Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal Carcinoma

Recruiting

646

RoW

Radiotherapy

Fudan University

Esophageal Squamous Cell Carcinoma

10/23

10/25

NCT04519905: Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)

Recruiting

320

RoW

Paclitaxel plus carboplatin, radiotherapy

Fudan University, Huadong Hospital, Jiangsu Cancer Institute & Hospital, Gansu Cancer Hospital, The First Affiliated Hospital of Xiamen University, Fujian Cancer Hospital, Taihe Hospital, Wuxi No. 4 People's Hospital, Ningbo No.2 Hospital

Esophageal Squamous Cell Carcinoma, Chemoradiotherapy, Survival

12/24

12/27

NCT05425472: A Phase II Study of HR070803 in the Treatment of Advanced Esophageal Cancer

Recruiting

RoW

HR070803

Jiangsu HengRui Medicine Co., Ltd.

Advanced Esophageal Cancer

01/23

03/23

NCT04764227: Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)

Active, not recruiting

RoW

Paclitaxel, Carboplatin, Radiotherapy

Fudan University

Esophagus Cancer, Esophageal Squamous Cell Carcinoma, Chemoradiotherapy, Radiation Therapy, Postoperative

03/24

03/27

NCT05131763: NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors

Recruiting

RoW

NKG2D-based CAR T-cells

Fudan University, KAEDI

Hepatocellular Carcinoma, Glioblastoma, Medulloblastoma, Colon Cancer

12/22

12/23

NCT04694391: Genomic Study of Relapse Esophageal Cancer After Radiotherapy

Recruiting

N/A

200

RoW

whole exome sequence

Fudan University, M.D. Anderson Cancer Center, Nantong University, Jiangsu Cancer Institute & Hospital, Henan Cancer Hospital, Ningbo No.2 Hospital, Taihe Hospital, Taian Cancer Hospital

Gene Mutation-Related Cancer, Esophageal Cancer, Radiation Exposure

12/20

12/22

NCT06393140: The Study on the Mechanism of Radiotherapy-elicited Immune Response

Recruiting

N/A

200

RoW

Fudan University

Esophageal Carcinoma Salivary Gland Type, Radiotherapy

07/26

NCT05142709: Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.

Active, not recruiting

N/A

600

RoW

Anti-PD-1 Immune Checkpoint Inhibitors

Fudan University

Metastatic Esophageal Squamous Cell Carcinoma

09/23

12/24

NCT06652620: Cola Ingestion for Esophageal Bolus Impaction

Recruiting

N/A

RoW

Cola

Fudan University

Esophageal Cancer

10/25

06/26

NCT05760391: A Study of IO Plus Radiotherapy in Patients With Advanced ESCC.

Recruiting

N/A

100

RoW

Radiotherapy

Fudan University

Metastatic Esophageal Squamous Cell Carcinoma

02/25

08/26

NCT05426850: ctDNA-based MRD Assessment in Local Advanced Esophageal Carcinoma

Recruiting

N/A

100

RoW

Fudan University

Esophageal Squamous Cell Carcinoma

12/22

12/24

Wang, hongxia

NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer

Recruiting

560

RoW

Irinotecan Hydrochloride Injection, HX008, Placebo

Taizhou Hanzhong biomedical co. LTD

Stomach Cancer

08/23

TORCHLIGHT, NCT04085276: Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment

Active, not recruiting

531

RoW

JS001, Nab-Paclitaxel, Placebo

Shanghai Junshi Bioscience Co., Ltd.

Triple-Negative Breast Cancer

12/24

12/25

NCT06551051: ADC-induced Neurotoxicity Treated With Duloxetine

Recruiting

RoW

duloxetine, duloxetine hydrochloride

Fudan University

Solid Tumour

12/25

NCT06636981: All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II Trial

Recruiting

129

RoW

Cohort2: ATRA+Toripalimab+TPC, Cohort1: ATRA+Toripalimab+chemo

Fudan University

Triple Negative Breast Cancer (TNBC)

09/29

NCT06683846: Ivocizumab in the Treatment of Multiple Advanced Tumors

Recruiting

400

RoW

Ivocizumab

Fudan University

Pheochromocytoma/Paraganglioma, Rhabdomyosarcoma, Paget Disease, Extramammary, Renal Angiomyolipoma, Perivascular Epithelioid Cell Tumor, Malignant, Sarcoma, Urachal Cancer, Neuroendocrine Cancer, Basal Cell Carcinomas, Sarcomatoid Carcinoma, Penile Cancer, Adrenal Cortical Cancer, Germ Cell Cancer Metastatic, Non-Clear Cell Renal Cell Carcinoma, Prostate Cancers, Clear Cell Renal Cancer, Urothelial Carcinoma, Kidney Cancer, Rare Tumors

11/27

NCT06684327: Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors

Recruiting

100

RoW

Albumin-paclitaxel Injection

Fudan University

Paget Disease, Extramammary, Rhabdomyosarcoma, Testicular Cancer, Penile Cancer, Urachal Cancer

12/26

12/27

NCT06470672: Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer

Not yet recruiting

RoW

SHR-A1921, Adebrelimab

Fudan University

Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

03/26

07/26

NCT06718933: Study of SHR-A1811 Combined with Pyrotinib and Bevacizumab in Advanced Breast Cancer with Brain Metastasis

Recruiting

1/2

RoW

SHR-A1811, Bevacizumab, Pyrotinib

Fudan University

Breast Cancer Metastatic, Breast Cancer Brain Metastases

08/26

02/27

NCT06682780: A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours

Not yet recruiting

1/2

320

RoW

LM-2417, Docetaxel, Toripalimab/Tirelizumab, Carboplatin, Niraparib, Lenvatinib

LaNova Medicines Limited

Advanced Solid Tumor

12/27

12/29

NCT06220838: Study SC-101 in Subjects With Advanced Malignancies

Recruiting

100

RoW

SC-101

Tianjin ConjuStar Biologics Co., Ltd.

Advanced Solid Tumor

03/26

09/26

NCT06426680: A Study of the ILB-3101 in Patients with Advanced Solid Tumors

Recruiting

240

RoW

ILB-3101

Innolake Biopharm

Advanced Solid Tumor

12/25

03/26

NCT06710158: Study of SC-102 in Patients With Advanced Solid Tumors

Recruiting

120

RoW

SC-102

Tianjin ConjuStar Biologics Co., Ltd.

Advanced Solid Cancers

12/26

06/27

NCT06718946: Study on the Safety and Efficacy of Intravenous Administration of IDOV-SAFETM in the Treatment of Advanced Solid Tumors

Recruiting

RoW

IDOV-SAFE

Fudan University

Advanced Malignant Solid Tumor

12/25

12/27

NCT06718621: A Study of BL-M08D1 in Patients With Locally Advanced or Metastatic Solid Tumors

Recruiting

RoW

BL-M08D1

Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Solid Tumor

12/26

06/27

NCT06713148: Study on the Safety and Efficacy of Intratumoral Administration of IDOV-SAFETM in the Treatment of Advanced Solid Tumors

Not yet recruiting

IDOV-SAFETM

Fudan University

Advanced Malignant Solid Tumor

12/25

12/27

NCT05831033: Safety and Efficacy of an Autologous Tumor Infiltrating Lymphocyte (TIL) Therapy in Patients with Advanced Solid Tumors

Recruiting

RoW

BEN101

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Renji Hospital, Shanghai, Fudan University

Solid Tumor

02/27

06/27

NCT06889610: A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.

Not yet recruiting

N/A

RoW

MTT(Multimodal Tumor Thermal Therapy System)- Triple-Negative Breast Cancer, MTT(Multimodal Tumor Thermal Therapy System)- Melanoma

Fudan University

Triple Negative Breast Cancer Metastatic, Melanoma Metastatic

07/26

05/28

NCT04676620: Comparison of Anterior Corneal Optical Aberration Induced by CK and Hyperopic LASIK

Recruiting

N/A

RoW

CK surgery

Wang Hongxia, Tianjin Eye Hospital

Refractive Error

12/21

Hu, Hong

HEROIC, NCT06551220: Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer with Different HER2 Expression Patterns

Recruiting

N/A

800

RoW

Trastuzumab Deruxtecan

Sun Yat-sen University

Metastatic Breast Cancer

01/25

ALMPILN, NCT05094882: Anatomical Location and Metastasis Pattern of Intrapulmonary Lymph Nodes in NSCLC (ECTOP-1010)

Recruiting

N/A

500

RoW

pulmonary lobectomy

Fudan University

Carcinoma, Non-small Cell Lung Cancer

12/23

06/24

Haiquan, Chen

NCT06561620: Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients

Recruiting

592

RoW

Befotertinib

Fudan University

3-year Disease-free Survival

05/27

05/29

NCT06097910: Surveillance for Multifocal GGNs

Recruiting

370

RoW

Watchful waiting

Fudan University

Lung Ground-glass Opacities, Active Surveillance

11/36

NCT06031181: Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019)

Recruiting

390

RoW

Sublobar Resection

Fudan University

Lung Adenocarcinoma, Frozen Section, Sublobar Resection

01/26

12/30

ACTPI, NCT03380468: Adjuvant Chemotherapy for High Risk Stage I Lung Adenocarcinoma

Recruiting

2/3

300

RoW

cisplatin plus pemetrexed

Fudan University

Lung Neoplasms

01/24

12/25

HYPERION, NCT05281003: Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)

Recruiting

128

RoW

Pembrolizumab, Keytruda, MK-3475, Paclitaxel, Cisplatin

Fudan University, Merck Sharp & Dohme LLC

Esophageal Squamous Cell Carcinoma

09/23

09/26

NCT06349252: Survival Validation and Gene Mutations of N Descriptors in the Ninth Edition of the TNM Classification for Lung Cancer

Recruiting

N/A

1263

RoW

Radical resection

Fudan University

Non-small Cell Lung Cancer

08/24

01/25

NCT03689439: Is Bone Scintigraphy Necessary in cT1N0M0 GGO Non-Small Cell Lung Cancer? (ECTOP-1006)

Completed

N/A

1000

RoW

bone scintigraphy

Fudan University

Bone Metastases

11/21

11/22

NCT05252676: Evaluation of Correlations Between Radiologic Features and Pathologic Subtypes of GGO LUAD Via WMS (ECTOP-1011)

Completed

N/A

103

RoW

Fudan University

Adenocarcinoma of Lung

08/22

12/22

CONCORD-C, NCT05794724: Intraoperative Frozen Section Pathology to Guide Surgical Treatment for Lung Adenocarcinoma (ECTOP-1016)

Recruiting

N/A

1063

RoW

Surgical resection

Fudan University

Lung Adenocarcinoma, Surgical Procedure, Unspecified, Pathology

12/23

NCT05794711: Intraoperative Frozen Section Pathology to Guide Surgical Treatment for Lung Adenocarcinoma (ECTOP-1015)

Recruiting

N/A

1063

RoW

Surgical resection

Fudan University

Lung Adenocarcinoma, Surgical Procedure, Unspecified, Pathology

12/23

12/24

NCT05794698: Intraoperative Frozen Section Pathology to Diagnose the IASLC Grades for Lung Adenocarcinoma (ECTOP-1014)

Completed

N/A

827

RoW

Surgical resection

Fudan University, Shanghai Pulmonary Hospital, Shanghai, China, Tongji Hospital, Wuhan, Hubei Province, China, Sixth People's Hospital, Shanghai, China, Ningbo Clinical Pathological Diagnostic Center, Ningbo, Zhejiang Province, China, Dongfang Hospital Affiliated to Tongji University, Shanghai, China, Minhang Hospital Affiliated to Fudan University, Shanghai, China, People's Hospital of Jiangdu, Yangzhou, Jiangsu Province, China, Liaocheng People's Second Hospital, Liaocheng, Shandong Province, China, Guanxian People's Hospital, Liaocheng, Shandong Province, China, Zhoupu Hospital, Pudong New Area, Shanghai, China

Lung Adenocarcinoma, Surgical Procedure, Unspecified, Pathology

06/24

08/24

ECTOP-1023, NCT06547710: Primary Tumor Resection for M1a Stage Lung Cancer

Recruiting

N/A

RoW

Fudan University

Lung Cancer Metastatic, Surgical Resection

12/25

06/26

zhang, sheng

PETARDS, NCT05658692: Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome

Recruiting

1000

RoW

protective ventilation, prone position ventilation, glucocorticoid therapy, Dexamethasone, Hydrocortisone, restrictive fluid resuscitation, Thymosin Alpha, Muscle relaxant therapy, Vecuronium Bromide, Succinylcholine, Integrated Chinese and Western Medicine Treatment, statin therapy, Simvastatin, Rosuvastatin, anti-infective treatment, Extracorporeal Membrane Oxygenation（ECMO）, stem cell therapy, Sedative analgesia/muscle relaxant therapy, Propofol, midazolam, dexmedetomidine, inotropes therapy, Dopamine, Olprinone, Levosimendan, Vasoactive drug therapy, Norepinephrine, epinephrine, metaraminol, isoproterenol

Second Affiliated Hospital, School of Medicine, Zhejiang University, Renmin Hospital of Wuhan University, The Second Affiliated Hospital of Harbin Medical University, West China Hospital, The First Affiliated Hospital of Zhengzhou University, Peking Union Medical College Hospital, Wuhan Union Hospital, China, Fudan University, Guangdong Provincial People's Hospital, Ningbo No. 1 Hospital, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University

Acute Respiratory Distress Syndrome

10/23

12/23

DIVA, NCT06530732: Deep Cervical Lymphatlc-Venous Anastomosis Surgery for the Treatment of Alzheimer's Disease: A Pilot Study ( Study)

Recruiting

RoW

Deep Cervical lymphatlc-Venous Anastomosis Surgery, Lecanemab

Zhejiang Provincial People's Hospital

Alzheimer's Disease

06/26

09/26

NCT06530537: Cilostazol vs. Aspirin in Acute Non-cardioembolic Stroke With Cerebral mIcrobleeds

Recruiting

848

RoW

Cilostazol, Aspirin

Zhejiang Provincial People's Hospital

Cerebral Microbleeds, Stroke

08/31

NCT05330871: Evaluate the Safety and Immunogenicity of Ad5 COVID-19 Vaccines for Booster Use in Children Aged 6-17 Years.

Active, not recruiting

410

RoW

1 Nebulized inhalation for booster groups, Recombinant COVID-19 Vaccine for Inhalation, 2 Nebulized inhalation for booster groups, 3 Nebulized inhalation for booster groups, 4 Nebulized inhalation for booster groups, 5 Intramuscular injection for booster groups, Recombinant Corona Virus Vaccine (Adenovirus Type 5 Vector), 6 Intramuscular injection for booster groups, 7 Intramuscular injection for booster groups, 8 Intramuscular injection for booster groups, Inactivated COVID-19 Vaccine, 9 Intramuscular injection for booster groups, 10 Intramuscular injection for booster groups, 11 Nebulized inhalation for booster groups, 12 Nebulized inhalation for booster groups, 13 Nebulized inhalation for booster groups, 14 Nebulized inhalation for booster groups, 15 Intramuscular injection for booster groups, 16 Intramuscular injection for booster groups, 17 Intramuscular injection for booster groups, 18 Intramuscular injection for booster groups, 19 Intramuscular injection for booster groups, 20 Intramuscular injection for booster groups, 21 Nebulized inhalation for primary groups, 22 Nebulized inhalation for primary groups, 23 Nebulized inhalation for primary groups, 24 Nebulized inhalation for primary groups

Seventh Medical Center of PLA General Hospital

COVID-19

06/22

05/23

NCT05765825: Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC

Recruiting

RoW

serplulimab, HLX10, Cisplatin, Cisplatin injection, Carboplatin, Carboplatin injection, Etoposide, Etoposide injection, Thoracic radiation therapy (TRT), low-dose radiotherapy

Sichuan University

Extensive-stage Small-cell Lung Cancer

06/24

12/25

NCT06551051: ADC-induced Neurotoxicity Treated With Duloxetine

Recruiting

RoW

duloxetine, duloxetine hydrochloride

Fudan University

Solid Tumour

12/25

NCT05148533: A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor

Terminated

1/2

RoW

TJ1133 Injection

TJ Biopharma Co., Ltd.

Advanced Solid Tumor

02/23

DREAM-10, NCT06164262: Dementia Risk Registry for Young and Middle-aged CSVD Patients in the Next 10 Years

Recruiting

N/A

1000

RoW

Individuals with CSVD

Zhejiang Provincial People's Hospital

Cerebral Small Vessel Diseases, Dementia, Mixed, Health Behavior, Health Behavior, Risky

08/34

12/34

EMBRACE, NCT06451887: Early Identification of Malignant Brain Edema in laRge Artery oCclusive Stroke After Endovascular Therapy ( Study)

Recruiting

N/A

1950

RoW

Zhejiang Provincial People's Hospital

Endovascular Therapy, Brain Edema, Prediction Model, Ischemic Stroke

03/27

06/27

FRESH-CSVD, NCT06431711: Fundus Optical coheRence Tomography Angiography Evaluation for Small-vessel Health in Cerebral Small Vessel Disease

Recruiting

N/A

2400

RoW

Zhejiang Provincial People's Hospital

Cerebral Small Vessel Diseases, Retinal Ischemia, Choroid; Injury

03/29

03/34

RECAS, NCT06031610: Revascularization Effect on CSVD Burden in Carotid Artery Stenosis

Recruiting

N/A

1000

RoW

carotid artery stenting, drug therapy

Zhejiang Provincial People's Hospital

Carotid Artery Stenosis, Cerebral Small Vessel Diseases

12/33

05/34

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Wang, Zhonghua

Renaissance, NCT05076682: Reverse Triple Negative Immune Resistant Breast Cancer

Recruiting

RoW

Choline, anti-PD-1 antibody and chemotherapy, Sodium Cromoglicate, Efavirenz

Fudan University

Triple-negative Breast Cancer

12/22

03/23

Resilire, NCT06731140: Reverse Luminal Immune Resistant Breast Cancer

Recruiting

RoW

Retinoic Acid, anti-PD-1 antibody and chemotherapy

Fudan University

Luminal Breast Cancer

07/26

10/26

Chen, Haiquan

NCT06634966: Segmentectomy for Solid-dominant Lung Cancer

Recruiting

277

RoW

Segmentectomy, Segment resection

Fudan University

Segmentectomy, Lung Adenocarcinoma

12/26

06/27

NCT06031246: Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018)

Recruiting

634

RoW

Selective Lymph Node Dissection

Fudan University

Lung Adenocarcinoma, Lymph Node Metastasis

01/26

12/30

SEFOGI, NCT05717803: Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012)

Recruiting

307

RoW

Segmentectomy, Segment resection, Segment removal

Fudan University

Segmentectomy, Lung Adenocarcinoma

12/28

12/29

ACTPI, NCT03380468: Adjuvant Chemotherapy for High Risk Stage I Lung Adenocarcinoma

Recruiting

2/3

300

RoW

cisplatin plus pemetrexed

Fudan University

Lung Neoplasms

01/24

12/25

HYPERION, NCT05281003: Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)

Recruiting

128

RoW

Pembrolizumab, Keytruda, MK-3475, Paclitaxel, Cisplatin

Fudan University, Merck Sharp & Dohme LLC

Esophageal Squamous Cell Carcinoma

09/23

09/26

NCT06152978: A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma

Not yet recruiting

182

RoW

Sintilimab, Chemotherapy

Fudan University, Innovent Biologics (Suzhou) Co. Ltd.

Esophageal Squamous Cell Carcinoma

12/25

12/27

NCT06572722: Perioperative Immunotherapy for NSCLC (ECTOP-1030)

Not yet recruiting

200

Atezolizumab, Nivolumab, Pembrolizumab

Fudan University

Lung Cancer

09/26

09/29

NCT03591445: Is Bronchoscopy Necessary in the Preoperative Workup of GGO Lung Cancer?(ECTOP-1005)

Completed

N/A

615

RoW

Flexible Bronchoscopy

Pulmonary Nodule, Solitary

11/19

06/20

NCT03689439: Is Bone Scintigraphy Necessary in cT1N0M0 GGO Non-Small Cell Lung Cancer? (ECTOP-1006)

Completed

N/A

1000

RoW

bone scintigraphy

Fudan University

Bone Metastases

11/21

11/22

NCT05252676: Evaluation of Correlations Between Radiologic Features and Pathologic Subtypes of GGO LUAD Via WMS (ECTOP-1011)

Completed

N/A

103

RoW

Fudan University

Adenocarcinoma of Lung

08/22

12/22

NCT04527419: SLND or Not in cT1 GGO Invasive Lung Adenocarcinoma (ECTOP-1009)

Recruiting

N/A

638

RoW

Systematically mediastinal lymph node dissection, No mediastinal lymph node dissection

Fudan University

Carcinoma, Non-Small-Cell Lung

02/24

02/27

NCT06634979: Selective Lymph Node Resection for Invasive Non-small Cell Lung Cancer with the CTR of 0.5-1 and the Diameter of ≤ 2 Cm

Recruiting

N/A

684

RoW

Selective lymph node dissection

Fudan University

Lung Cancer (NSCLC), Lymph Node Dissection

05/26

05/29

NCT05443841: Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)

Recruiting

N/A

385

RoW

pleural lavage

Fudan University

Esophageal Cancer

07/24

07/27

Fu, Xiao-Long

NCT05177497: SHR-1701 for Consolidation Therapy After Concurrent Chemoradiotherapy in Inoperable Stage III NSCLC

Not yet recruiting

SHR-1701

Shanghai Chest Hospital

NSCLC, Stage III

07/24

10/24

Xiang, Jiaqing

NCT03273647: Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma With Positive Circumstantial Resection Margin

Not yet recruiting

radiation

Fudan University

Esophageal Squamous Cell Carcinoma, Positive Circumferential Resection Margin

12/19

12/24

Zhao, Kuaile

NCT06190782: Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor

Recruiting

354

RoW

PD-1 inhibitor+/- chemotherapy combined with local therapy, systemic therapy alone, the systemic therapy only

Fudan University

Esophageal Squamous Cell Carcinoma, Oligometastatic Disease, Radiotherapy

09/25

09/27

NCT03790553: Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal Carcinoma

Recruiting

646

RoW

Radiotherapy

Fudan University

Esophageal Squamous Cell Carcinoma

10/23

10/25

NCT04519905: Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)

Recruiting

320

RoW

Paclitaxel plus carboplatin, radiotherapy

Esophageal Squamous Cell Carcinoma, Chemoradiotherapy, Survival

12/24

12/27

NCT05425472: A Phase II Study of HR070803 in the Treatment of Advanced Esophageal Cancer

Recruiting

RoW

HR070803

Jiangsu HengRui Medicine Co., Ltd.

Advanced Esophageal Cancer

01/23

03/23

NCT04764227: Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)

Active, not recruiting

RoW

Paclitaxel, Carboplatin, Radiotherapy

Fudan University

Esophagus Cancer, Esophageal Squamous Cell Carcinoma, Chemoradiotherapy, Radiation Therapy, Postoperative

03/24

03/27

NCT05131763: NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors

Recruiting

RoW

NKG2D-based CAR T-cells

Fudan University, KAEDI

Hepatocellular Carcinoma, Glioblastoma, Medulloblastoma, Colon Cancer

12/22

12/23

NCT04694391: Genomic Study of Relapse Esophageal Cancer After Radiotherapy

Recruiting

N/A

200

RoW

whole exome sequence

Fudan University, M.D. Anderson Cancer Center, Nantong University, Jiangsu Cancer Institute & Hospital, Henan Cancer Hospital, Ningbo No.2 Hospital, Taihe Hospital, Taian Cancer Hospital

Gene Mutation-Related Cancer, Esophageal Cancer, Radiation Exposure

12/20

12/22

NCT06393140: The Study on the Mechanism of Radiotherapy-elicited Immune Response

Recruiting

N/A

200

RoW

Fudan University

Esophageal Carcinoma Salivary Gland Type, Radiotherapy

07/26

NCT05142709: Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.

Active, not recruiting

N/A

600

RoW

Anti-PD-1 Immune Checkpoint Inhibitors

Fudan University

Metastatic Esophageal Squamous Cell Carcinoma

09/23

12/24

NCT06652620: Cola Ingestion for Esophageal Bolus Impaction

Recruiting

N/A

RoW

Cola

Fudan University

Esophageal Cancer

10/25

06/26

NCT05760391: A Study of IO Plus Radiotherapy in Patients With Advanced ESCC.

Recruiting

N/A

100

RoW

Radiotherapy

Fudan University

Metastatic Esophageal Squamous Cell Carcinoma

02/25

08/26

NCT05426850: ctDNA-based MRD Assessment in Local Advanced Esophageal Carcinoma

Recruiting

N/A

100

RoW

Fudan University

Esophageal Squamous Cell Carcinoma

12/22

12/24

Wang, hongxia

NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer

Recruiting

560

RoW

Irinotecan Hydrochloride Injection, HX008, Placebo

Taizhou Hanzhong biomedical co. LTD

Stomach Cancer

08/23

TORCHLIGHT, NCT04085276: Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment

Active, not recruiting

531

RoW

JS001, Nab-Paclitaxel, Placebo

Shanghai Junshi Bioscience Co., Ltd.

Triple-Negative Breast Cancer

12/24

12/25

NCT06551051: ADC-induced Neurotoxicity Treated With Duloxetine

Recruiting

RoW

duloxetine, duloxetine hydrochloride

Fudan University

Solid Tumour

12/25

NCT06636981: All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II Trial

Recruiting

129

RoW

Cohort2: ATRA+Toripalimab+TPC, Cohort1: ATRA+Toripalimab+chemo

Fudan University

Triple Negative Breast Cancer (TNBC)

09/29

NCT06683846: Ivocizumab in the Treatment of Multiple Advanced Tumors

Recruiting

400

RoW

Ivocizumab

Fudan University

11/27

NCT06684327: Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors

Recruiting

100

RoW

Albumin-paclitaxel Injection

Fudan University

Paget Disease, Extramammary, Rhabdomyosarcoma, Testicular Cancer, Penile Cancer, Urachal Cancer

12/26

12/27

NCT06470672: Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer

Not yet recruiting

RoW

SHR-A1921, Adebrelimab

Fudan University

Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

03/26

07/26

NCT06718933: Study of SHR-A1811 Combined with Pyrotinib and Bevacizumab in Advanced Breast Cancer with Brain Metastasis

Recruiting

1/2

RoW

SHR-A1811, Bevacizumab, Pyrotinib

Fudan University

Breast Cancer Metastatic, Breast Cancer Brain Metastases

08/26

02/27

NCT06682780: A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours

Not yet recruiting

1/2

320

RoW

LM-2417, Docetaxel, Toripalimab/Tirelizumab, Carboplatin, Niraparib, Lenvatinib

LaNova Medicines Limited

Advanced Solid Tumor

12/27

12/29

NCT06220838: Study SC-101 in Subjects With Advanced Malignancies

Recruiting

100

RoW

SC-101

Tianjin ConjuStar Biologics Co., Ltd.

Advanced Solid Tumor

03/26

09/26

NCT06426680: A Study of the ILB-3101 in Patients with Advanced Solid Tumors

Recruiting

240

RoW

ILB-3101

Innolake Biopharm

Advanced Solid Tumor

12/25

03/26

NCT06710158: Study of SC-102 in Patients With Advanced Solid Tumors

Recruiting

120

RoW

SC-102

Tianjin ConjuStar Biologics Co., Ltd.

Advanced Solid Cancers

12/26

06/27

NCT06718946: Study on the Safety and Efficacy of Intravenous Administration of IDOV-SAFETM in the Treatment of Advanced Solid Tumors

Recruiting

RoW

IDOV-SAFE

Fudan University

Advanced Malignant Solid Tumor

12/25

12/27

NCT06718621: A Study of BL-M08D1 in Patients With Locally Advanced or Metastatic Solid Tumors

Recruiting

RoW

BL-M08D1

Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Solid Tumor

12/26

06/27

NCT06713148: Study on the Safety and Efficacy of Intratumoral Administration of IDOV-SAFETM in the Treatment of Advanced Solid Tumors

Not yet recruiting

IDOV-SAFETM

Fudan University

Advanced Malignant Solid Tumor

12/25

12/27

NCT05831033: Safety and Efficacy of an Autologous Tumor Infiltrating Lymphocyte (TIL) Therapy in Patients with Advanced Solid Tumors

Recruiting

RoW

BEN101

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Renji Hospital, Shanghai, Fudan University

Solid Tumor

02/27

06/27

NCT06889610: A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.

Not yet recruiting

N/A

RoW

MTT(Multimodal Tumor Thermal Therapy System)- Triple-Negative Breast Cancer, MTT(Multimodal Tumor Thermal Therapy System)- Melanoma

Fudan University

Triple Negative Breast Cancer Metastatic, Melanoma Metastatic

07/26

05/28

NCT04676620: Comparison of Anterior Corneal Optical Aberration Induced by CK and Hyperopic LASIK

Recruiting

N/A

RoW

CK surgery

Wang Hongxia, Tianjin Eye Hospital

Refractive Error

12/21

Hu, Hong

HEROIC, NCT06551220: Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer with Different HER2 Expression Patterns

Recruiting

N/A

800

RoW

Trastuzumab Deruxtecan

Sun Yat-sen University

Metastatic Breast Cancer

01/25

ALMPILN, NCT05094882: Anatomical Location and Metastasis Pattern of Intrapulmonary Lymph Nodes in NSCLC (ECTOP-1010)

Recruiting

N/A

500

RoW

pulmonary lobectomy

Fudan University

Carcinoma, Non-small Cell Lung Cancer

12/23

06/24

Haiquan, Chen

NCT06561620: Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients

Recruiting

592

RoW

Befotertinib

Fudan University

3-year Disease-free Survival

05/27

05/29

NCT06097910: Surveillance for Multifocal GGNs

Recruiting

370

RoW

Watchful waiting

Fudan University

Lung Ground-glass Opacities, Active Surveillance

11/36

NCT06031181: Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019)

Recruiting

390

RoW

Sublobar Resection

Fudan University

Lung Adenocarcinoma, Frozen Section, Sublobar Resection

01/26

12/30

ACTPI, NCT03380468: Adjuvant Chemotherapy for High Risk Stage I Lung Adenocarcinoma

Recruiting

2/3

300

RoW

cisplatin plus pemetrexed

Fudan University

Lung Neoplasms

01/24

12/25

HYPERION, NCT05281003: Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)

Recruiting

128

RoW

Pembrolizumab, Keytruda, MK-3475, Paclitaxel, Cisplatin

Fudan University, Merck Sharp & Dohme LLC

Esophageal Squamous Cell Carcinoma

09/23

09/26

NCT06349252: Survival Validation and Gene Mutations of N Descriptors in the Ninth Edition of the TNM Classification for Lung Cancer

Recruiting

N/A

1263

RoW

Radical resection

Fudan University

Non-small Cell Lung Cancer

08/24

01/25

NCT03689439: Is Bone Scintigraphy Necessary in cT1N0M0 GGO Non-Small Cell Lung Cancer? (ECTOP-1006)

Completed

N/A

1000

RoW

bone scintigraphy

Fudan University

Bone Metastases

11/21

11/22

NCT05252676: Evaluation of Correlations Between Radiologic Features and Pathologic Subtypes of GGO LUAD Via WMS (ECTOP-1011)

Completed

N/A

103

RoW

Fudan University

Adenocarcinoma of Lung

08/22

12/22

CONCORD-C, NCT05794724: Intraoperative Frozen Section Pathology to Guide Surgical Treatment for Lung Adenocarcinoma (ECTOP-1016)

Recruiting

N/A

1063

RoW

Surgical resection

Fudan University

Lung Adenocarcinoma, Surgical Procedure, Unspecified, Pathology

12/23

NCT05794711: Intraoperative Frozen Section Pathology to Guide Surgical Treatment for Lung Adenocarcinoma (ECTOP-1015)

Recruiting

N/A

1063

RoW

Surgical resection

Fudan University

Lung Adenocarcinoma, Surgical Procedure, Unspecified, Pathology

12/23

12/24

NCT05794698: Intraoperative Frozen Section Pathology to Diagnose the IASLC Grades for Lung Adenocarcinoma (ECTOP-1014)

Completed

N/A

827

RoW

Surgical resection

Lung Adenocarcinoma, Surgical Procedure, Unspecified, Pathology

06/24

08/24

ECTOP-1023, NCT06547710: Primary Tumor Resection for M1a Stage Lung Cancer

Recruiting

N/A

RoW

Fudan University

Lung Cancer Metastatic, Surgical Resection

12/25

06/26

zhang, sheng

PETARDS, NCT05658692: Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome

Recruiting

1000

RoW

Acute Respiratory Distress Syndrome

10/23

12/23

DIVA, NCT06530732: Deep Cervical Lymphatlc-Venous Anastomosis Surgery for the Treatment of Alzheimer's Disease: A Pilot Study ( Study)

Recruiting

RoW

Deep Cervical lymphatlc-Venous Anastomosis Surgery, Lecanemab

Zhejiang Provincial People's Hospital

Alzheimer's Disease

06/26

09/26

NCT06530537: Cilostazol vs. Aspirin in Acute Non-cardioembolic Stroke With Cerebral mIcrobleeds

Recruiting

848

RoW

Cilostazol, Aspirin

Zhejiang Provincial People's Hospital

Cerebral Microbleeds, Stroke

08/31

NCT05330871: Evaluate the Safety and Immunogenicity of Ad5 COVID-19 Vaccines for Booster Use in Children Aged 6-17 Years.

Active, not recruiting

410

RoW

Seventh Medical Center of PLA General Hospital

COVID-19

06/22

05/23

NCT05765825: Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC

Recruiting

RoW

serplulimab, HLX10, Cisplatin, Cisplatin injection, Carboplatin, Carboplatin injection, Etoposide, Etoposide injection, Thoracic radiation therapy (TRT), low-dose radiotherapy

Sichuan University

Extensive-stage Small-cell Lung Cancer

06/24

12/25

NCT06551051: ADC-induced Neurotoxicity Treated With Duloxetine

Recruiting

RoW

duloxetine, duloxetine hydrochloride

Fudan University

Solid Tumour

12/25

NCT05148533: A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor

Terminated

1/2

RoW

TJ1133 Injection

TJ Biopharma Co., Ltd.

Advanced Solid Tumor

02/23

DREAM-10, NCT06164262: Dementia Risk Registry for Young and Middle-aged CSVD Patients in the Next 10 Years

Recruiting

N/A

1000

RoW

Individuals with CSVD

Zhejiang Provincial People's Hospital

Cerebral Small Vessel Diseases, Dementia, Mixed, Health Behavior, Health Behavior, Risky

08/34

12/34

EMBRACE, NCT06451887: Early Identification of Malignant Brain Edema in laRge Artery oCclusive Stroke After Endovascular Therapy ( Study)

Recruiting

N/A

1950

RoW

Zhejiang Provincial People's Hospital

Endovascular Therapy, Brain Edema, Prediction Model, Ischemic Stroke

03/27

06/27

FRESH-CSVD, NCT06431711: Fundus Optical coheRence Tomography Angiography Evaluation for Small-vessel Health in Cerebral Small Vessel Disease

Recruiting

N/A

2400

RoW

Zhejiang Provincial People's Hospital

Cerebral Small Vessel Diseases, Retinal Ischemia, Choroid; Injury

03/29

03/34

RECAS, NCT06031610: Revascularization Effect on CSVD Burden in Carotid Artery Stenosis

Recruiting

N/A

1000

RoW

carotid artery stenting, drug therapy

Zhejiang Provincial People's Hospital

Carotid Artery Stenosis, Cerebral Small Vessel Diseases

12/33

05/34

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites